Stage IIIA Breast Cancer Clinical Trial
Official title:
Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer
This pilot clinical trial studies how well pazopanib hydrochloride works in treating patients with breast cancer that is newly diagnosed or has come back at or near the same place as the original tumor and can be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by preventing the growth of new blood vessels necessary for tumor growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed.
PRIMARY OBJECTIVES:
I. To determine the biologic effect, measured by a decrease in phosphorylation of vascular
endothelial growth factor receptor 2 (VEGFR-2) and/or decrease in microvessel density, in
breast tumor biopsies after treatment with daily oral GW786034 (pazopanib hydrochloride) for
at least 12 consecutive days in early stage, operable breast cancer or local and/or regional
recurrence that is amenable to surgery.
II. To determine the mechanism of antitumor effect, measured by a reduction in tumor cell
proliferation (Ki67) or an increase in apoptosis in breast tumor biopsies after treatment
with GW786034.
SECONDARY OBJECTIVES:
I. To determine the change in levels of tissue vascular endothelial growth factor (VEGF) in
breast tumor biopsies after treatment with GW786034.
II. To evaluate the change in phosphorylation of epidermal growth factor receptor (EGFR),
mitogen-activated protein kinase (MAPK), and protein kinase B (AKT) in breast tumor biopsies
after treatment with GW786034.
III. To identify gene expression patterns in breast tumor biopsies before and after
treatment with GW786034.
IV. To evaluate the change in VEGF (in the plasma) and VEGFR-2 (in the serum) as circulating
biomarkers after treatment with GW786034.
V. To evaluate the change in circulating tumor cells in peripheral blood after treatment
with GW786034.
VI. To determine whether the steady-state plasma concentration of GW786034 correlates with
inhibition of phosphorylated (phospho)-VEGFR-2 and other endpoints in breast tumor biopsies.
VII. To evaluate the change in vascular permeability by dynamic contrast enhanced
(DCE)-magnetic resonance imaging (MRI) of the breast after treatment with GW786034.
VIII. To compare the images obtained with bilateral DCE-MRI of the breast before, during,
and after treatment with GW786034.
OUTLINE:
Patients receive pazopanib hydrochloride orally (PO) once daily (QD) for 12-20 days in the
absence of disease progression or unacceptable toxicity. Patients then undergo surgical
resection of tumor between days 13 and 21 (24 hours after completion of pazopanib
hydrochloride).
After completion of study treatment, patients are followed up within 30 days.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Terminated |
NCT02454777 -
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
|
N/A | |
Completed |
NCT03061175 -
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
|
N/A | |
Completed |
NCT01959490 -
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Terminated |
NCT01368263 -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT01928186 -
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
|
N/A | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00070252 -
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT01478477 -
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
|
N/A | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00416715 -
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
|
Phase 2 |